Steve Schonfeld’s Definium Therapeutics DFTX Stock Holding History

Steve Schonfeld’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.63M	Buy	119,610 +109,198	+1,049%	+$2.7M	0.02%	602
2026 Q1	$197K	Sell	10,412 -20,044	-66%	-$340K	﹤0.01%	1754
2025 Q4	$408K	Sell	30,456 -5,054	-14%	-$62.5K	﹤0.01%	1471
2025 Q3	$419K	Buy	+35,510	New	+$331K	﹤0.01%	1734
2023 Q1	–	Sell	-10,400	Closed	-$22.9K	–	2422
2022 Q4	$22.9K	Buy	+10,400	New	+$28.9K	﹤0.01%	2317

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Steve Schonfeld's DFTX Position: Q2 2026 in Review

Steve Schonfeld increased its Definium Therapeutics (DFTX) stake by 1,049% in Q2 2026, buying an estimated $2.7M and bringing the position to 119,610 shares worth $5.63M. The position accounts for 0.02% of the portfolio, ranked #602.

Steve Schonfeld first reported a position in DFTX in Q4 2022 and has held it in 5 quarters since. 360 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Steve Schonfeld held 119,610 shares of Definium Therapeutics worth $5.63M as of Q2 2026.
Steve Schonfeld bought 109,198 Definium Therapeutics shares in Q2 2026, an estimated $2.7M.
Definium Therapeutics made up 0.02% of Steve Schonfeld's portfolio in Q2 2026, its #602 holding.
Steve Schonfeld first reported a position in Definium Therapeutics in Q4 2022 and has held it in 5 quarters since.
360 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.